tiprankstipranks
Trending News
More News >
Avanos Medical (AVNS)
NYSE:AVNS
Advertisement

Avanos Medical (AVNS) AI Stock Analysis

Compare
172 Followers

Top Page

AVNS

Avanos Medical

(NYSE:AVNS)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$11.50
▼(-4.96% Downside)
Avanos Medical's overall stock score reflects strong revenue growth but significant profitability challenges and a negative valuation. The earnings call provided some positive insights, but was marred by a large impairment charge and tariff impacts. Technical indicators suggest a bearish trend, further weighing down the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Strategic Divestiture
Divesting non-core assets allows Avanos to focus resources on high-growth areas, enhancing strategic focus and operational efficiency.
Leadership Changes
New leadership can bring fresh perspectives and strategies, potentially improving financial management and corporate governance.
Negative Factors
Goodwill Impairment
Significant impairment charges reflect potential overvaluation of assets, impacting financial stability and investor confidence.
Profitability Challenges
Ongoing profitability issues can hinder reinvestment in growth initiatives and affect long-term financial health.
Tariff Impact
Tariff-related costs increase operational expenses, potentially reducing margins and affecting competitive pricing strategies.

Avanos Medical (AVNS) vs. SPDR S&P 500 ETF (SPY)

Avanos Medical Business Overview & Revenue Model

Company DescriptionAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
How the Company Makes MoneyAvanos Medical generates revenue primarily through the sale of its medical devices and products in the surgical and pain management sectors. Key revenue streams include direct sales to hospitals, healthcare systems, and outpatient facilities, as well as partnerships with distributors and third-party sellers. The company benefits from recurring revenue through the ongoing use of its products in various medical procedures. Additionally, Avanos has established strategic partnerships with healthcare providers and organizations to enhance product adoption, which contributes to its earnings. Factors such as product innovation, regulatory approvals, and market demand for minimally invasive surgical solutions also play a significant role in driving the company's financial performance.

Avanos Medical Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
Avanos reported a strong second quarter with positive growth in its Specialty Nutrition Systems and RFA business, supported by strategic divestitures and leadership changes. However, the quarter was also marked by significant challenges, including a large goodwill impairment charge, declines in certain business areas, and the impact of tariffs. Despite these challenges, the company reaffirmed its 2025 guidance.
Q2-2025 Updates
Positive Updates
Strong Second Quarter Performance
Avanos delivered a strong second quarter with net sales of $175 million, organic sales up 2% compared to a year ago, and $0.17 of adjusted diluted earnings per share. Adjusted EBITDA was $17 million, with adjusted gross margins of 55.7%.
Specialty Nutrition Systems Growth
The Specialty Nutrition Systems portfolio grew 5% organically year over year, reaffirming the #1 position in long-term, short-term, and neonatal enteral feeding. The neonatal solutions business grew greater than 12% compared to the prior year.
Radiofrequency Ablation Business Success
The RFA business posted near 14% growth compared to the previous year. Sustained growth in RFA generator capital sales enabled higher procedure volumes.
Hyaluronic Acid Divestiture
Avanos closed the sale of its hyaluronic acid product line, marking a significant step in its transformation strategy focused on growth in Specialty Nutrition Systems and Pain Management and Recovery.
Leadership Appointments
Scott Galovan was appointed as the new CFO, and David Pacitti was appointed to Avanos' Board of Directors.
Negative Updates
Goodwill Impairment Charge
A noncash impairment charge of $77 million was recorded in the Pain Management and Recovery reporting unit due to downward pressure on market capitalization.
Surgical Pain Business Decline
The Surgical Pain business was down compared to the prior year, impacted by the slower-than-anticipated implementation of the NOPAIN Act reimbursement decision.
Tariff Impact
Avanos incurred over $8 million in tariffs during the second quarter, with estimated tariff-related manufacturing costs of $15 million for the year.
Game Ready Portfolio Revenue Decline
The Game Ready portfolio posted slightly lower revenues than a year ago, with efforts underway to improve performance and expand profitability.
Hyaluronic Acid and Intravenous Infusion Revenue Decline
The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 20% during the second quarter.
Company Guidance
During the Avanos Second Quarter 2025 Earnings Conference Call, the company reaffirmed its 2025 financial guidance, projecting full-year revenue between $665 million and $685 million despite the impact of divesting the hyaluronic acid product line. They reported $175 million in net sales for the quarter, with organic sales growth of 2% compared to the previous year. The Specialty Nutrition Systems portfolio experienced a 5% organic growth, while the Pain Management and Recovery segment saw a 3.4% increase in normalized organic sales. The company also recorded an adjusted EBITDA of $17 million and adjusted diluted earnings per share of $0.17, with adjusted gross margins at 55.7% and SG&A expenses constituting 45.2% of revenue. A noncash impairment charge of $77 million was taken in the Pain Management and Recovery unit due to goodwill assessment. Additionally, Avanos anticipates $15 million in incremental tariff-related costs for the year and expects to generate approximately $40 million in free cash flow.

Avanos Medical Financial Statement Overview

Summary
Avanos Medical shows strong revenue growth of 47.9% TTM but faces significant profitability challenges with negative EBIT and net profit margins. The balance sheet is stable with low leverage, yet the negative return on equity indicates inefficiencies. Cash flow generation is positive, but declining free cash flow growth raises concerns about future liquidity.
Income Statement
45
Neutral
Avanos Medical's income statement shows a mixed performance. The company has experienced significant revenue growth of 47.9% TTM, indicating strong top-line expansion. However, profitability metrics are concerning, with negative EBIT and net profit margins, reflecting operational challenges. The gross profit margin remains relatively stable, but the negative net income highlights ongoing financial difficulties.
Balance Sheet
55
Neutral
The balance sheet of Avanos Medical presents a moderate financial position. The debt-to-equity ratio is low at 0.18, suggesting manageable leverage levels. However, the return on equity is negative, indicating inefficiencies in generating returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.
Cash Flow
50
Neutral
Cash flow analysis reveals a mixed scenario for Avanos Medical. Operating cash flow is positive, but the free cash flow has decreased by 22.9% TTM, indicating potential liquidity concerns. The operating cash flow to net income ratio is healthy, suggesting that cash generation is relatively strong compared to reported losses. However, the decline in free cash flow growth is a point of concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue692.50M687.80M673.30M684.10M744.60M714.80M
Gross Profit374.10M381.30M379.70M394.20M379.90M390.60M
EBITDA-424.70M-345.60M50.60M77.80M48.90M-2.00M
Net Income-463.20M-392.10M-61.80M50.50M6.30M-27.20M
Balance Sheet
Total Assets1.04B1.15B1.69B1.79B1.59B1.67B
Cash, Cash Equivalents and Short-Term Investments90.30M107.70M87.70M127.70M118.50M111.50M
Total Debt137.30M170.20M209.10M277.00M187.50M248.80M
Total Liabilities262.70M325.70M456.10M495.70M330.70M416.30M
Stockholders Equity776.30M828.50M1.24B1.29B1.26B1.26B
Cash Flow
Free Cash Flow87.90M82.90M14.60M71.60M66.30M-22.70M
Operating Cash Flow113.40M100.70M32.40M90.90M87.30M-2.50M
Investing Cash Flow-41.90M-27.50M21.60M-135.40M-21.00M-24.20M
Financing Cash Flow-75.70M-49.10M-94.20M56.70M-55.30M-70.00M

Avanos Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.10
Price Trends
50DMA
11.64
Positive
100DMA
12.02
Positive
200DMA
13.64
Negative
Market Momentum
MACD
0.11
Positive
RSI
52.43
Neutral
STOCH
36.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVNS, the sentiment is Positive. The current price of 12.1 is below the 20-day moving average (MA) of 12.16, above the 50-day MA of 11.64, and below the 200-day MA of 13.64, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 52.43 is Neutral, neither overbought nor oversold. The STOCH value of 36.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVNS.

Avanos Medical Risk Analysis

Avanos Medical disclosed 37 risk factors in its most recent earnings report. Avanos Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Avanos Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
533.28M-27.19-4.72%-19.52%94.65%
57
Neutral
508.79M-3.69-29.10%-1.36%-479.49%
54
Neutral
584.52M-4.53-26.99%4.84%0.85%
53
Neutral
569.66M-913.51-0.10%5.08%99.38%
52
Neutral
473.64M-10.03-11.75%26.08%-63.67%
49
Neutral
$561.47M45.80-46.17%1.48%-6091.13%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AVNS
Avanos Medical
11.55
-11.94
-50.83%
OFIX
Orthofix
14.38
-1.00
-6.50%
VREX
Varex Imaging
11.96
0.16
1.36%
KIDS
OrthoPediatrics
18.89
-7.27
-27.79%
BVS
Bioventus
6.76
-4.29
-38.82%
ZIMV
ZimVie Inc
18.91
3.32
21.30%

Avanos Medical Corporate Events

Business Operations and StrategyM&A Transactions
Avanos Medical Acquires Nexus Medical for Growth
Positive
Sep 15, 2025

On September 15, 2025, Avanos Medical announced the acquisition of Nexus Medical, a company known for its TKO® anti-reflux needleless connector technology. This acquisition aims to enhance Avanos’ Specialty Nutrition Systems business by integrating Nexus’ technology, which supports safer nutrition and medication delivery in critical care settings like NICUs and PICUs. The acquisition is expected to immediately boost Avanos’ revenue growth and earnings per share, reinforcing its strategy to provide innovative solutions in critical care.

The most recent analyst rating on (AVNS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Avanos Medical Appoints New CFO Amid Financial Challenges
Negative
Aug 5, 2025

On August 1, 2025, Avanos Medical appointed David Pacitti as a Board member and Scott Galovan as the Senior Vice President, Chief Financial Officer. The company reported a 1.9% increase in net sales for the second quarter of 2025, but faced a net loss of $76.8 million due to a $77.0 million goodwill impairment charge. Despite challenges, Avanos showed growth in its Specialty Nutrition Systems and Pain Management & Recovery segments, with strategic divestitures and restructuring efforts aimed at strengthening its market position.

The most recent analyst rating on (AVNS) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025